Proteasome inhibitors have been shown to exert some of their therapeutic effects, not only by their anti-tumor effect on myeloma cells but also through the off-target inhibition of the nuclear factor-kB (NF-kB) signaling pathway, which results in decreased RANKL-mediated osteoclastic differentiation [125]. This evidence concerns the gene TNFSF11 and plasma cell myeloma.